Medicines & Healthcare products Regulatory Agency

MHRA
Regulating Medicines and Medical Devices

[redacted]

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

www.gov.uk/mhra

28 March 2024

Dear [redacted]

FOI 24/209

Thank you for your email of 29 February 2024, where following the disclosure of information under FOI 23/908 you requested disclosure of

1. *Vaccine analysis prints embedded in the document "Public Yellow card summary 04.02.21"*
2. *Any other updates like the "Covid19 VBR EWG" which is dated the 4th February 2021. It seems to be called "Update on Covid19 vaccine Astrazeneca vaccine safety" and is also marked "Covid19 VBR EWG". I would like documents dated between February 2021 and April 2021.*

We can confirm that we hold the information requested. Please find attached the three vaccine analysis prints:

- COVID-19 mRNA Pfizer BioNTech Vaccine Analysis Print
- COVID-19 AstraZeneca Vaccine Analysis Print
- COVID-19 vaccine brand unspecified analysis Print

Regarding your second request, there was one more similar report on COVID-19 vaccine AstraZeneca Safety which was presented to the Commission on Human Medicines' Expert Working Group on COVID-19 vaccine benefit-risk (COVID-19 VBR EWG) within the timeframe specified, on 25 February 2021. Please find a redacted copy of this paper attached.

We are continuing to withhold some information in accordance with section 40(2) and section 41(1) of the FOI Act. We will explain these exemptions below. Section 40(2) applies when personal data relates to individuals. This information is withheld as it falls under the exemption in sections 40(2) and 40(3)(a)(i) of the FOIA, which relates to the personal data of which the applicant is not the data subject. Section 40(2) of the FOIA provides that personal data relating to other persons is exempt information if disclosure would breach the Data Protection Act 1998 (DPA). We consider that disclosure of this information is likely to breach the first data protection principle in Schedule 1 to the DPA, which relates to the fair and lawful processing of personal data. Therefore, we have concluded that this information is exempt from disclosure under section 40(2) read in conjunction with section 40(3)(a)(i) of the FOIA.

Medicines & Healthcare products Regulatory Agency

MHRA
Regulating Medicines and Medical Devices

I hope this information is helpful.

Yours sincerely,

FOI Team,

If you have a query about this email, please contact us.

If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the agency who has not previously been involved in your request. If you wish to pursue that option, please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF